Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges

Current Neuropharmacology

Volumn 15, Issue 5, 2017, Pages 789-798

  Salem, Haitham ^a,b   Nagpal, Caesa ^b   Pigott, Teresa ^b   Lucio Teixeira, Antonio ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b University of Texas Harris County Psychiatric Center   (United States)

Author keywords

Agitation; Akathisia; Anticholinergics; Antipsychotics; Benzodiazepines; Extrapyramidal signs; Movement disorders; Neuroleptics

Indexed keywords

ACETYLCYSTEINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PYRIDOXINE;

AGITATION; AKATHISIA; CLINICAL EVALUATION; EXTRAPYRAMIDAL SYNDROME; HUMAN; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROBIOLOGY; PREVALENCE; REVIEW; SLEEP DISORDER; ANIMAL; BIBLIOGRAPHIC DATABASE; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; MENTAL DISEASE; STATISTICS AND NUMERICAL DATA;

AKATHISIA, DRUG-INDUCED; ANIMALS; ANTIPSYCHOTIC AGENTS; DATABASES, BIBLIOGRAPHIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; MENTAL DISORDERS;

EID: 85025117054     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X14666161208153644     Document Type: Review

References (100)

1. Brüne, M. Ladislav Haskovec and 100 Years of Akathisia. Am. J. Psychiatry, 2002, 159(5), 727. [http://dx.doi.org/10.1176/appi.ajp.159.5.727]
2. Mohr, P; Volavka, J. Ladislav Haskovec and akathisia: 100th anniversary. Br. J. Psychiatry, 2002, 181(6), 537. a. doi: 10.1192/bjp.181.6.537-a
3. Rummel-Kluge, C.; Komossa, K.; Schwarz, S.; Hunger, H.; Schmid, F.; Kissling, W.; Davis, J.M.; Leucht, S. Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull., 2012, 38(1), 167-177. [http://dx.doi.org/10.1093/schbul/sbq042] [PMID: 20513652]
4. Kruse, W. Treatment of drug-induced extrapyramidal symptoms. (A comparative study of three antiparkinson agents). Dis. Nerv. Syst., 1960, 21, 79-81. [PMID: 14412284]
5. Peitl, M.V.; Prološčić, J.; Blažević-Zelić, S.; Skarpa-Usmiani, I.; Peitl, V. Symptoms of agitated depression and/or akathisia. Psychiatr. Danub., 2011, 23(1), 108-110.[PMID: 21448111]
6. Young, S.L.; Taylor, M.; Lawrie, S.M. First do no harm. A systematic review of the prevalence and management of antipsychotic adverse effects. J. Psychopharmacol. (Oxford), 2015, 29(4), 353-362. [http://dx.doi.org/10.1177/0269881114562090] [PMID: 25516373]
7. Lane, R.M. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J. Psychopharmacol. (Oxford), 1998, 12(2), 192-214. [http://dx.doi.org/10.1177/026988119801200212] [PMID: 9694033]
8. Lipinski, J.F., Jr; Mallya, G.; Zimmerman, P.; Pope, H.G., Jr Fluoxetine-induced akathisia: clinical and theoretical implications. J. Clin. Psychiatry, 1989, 50(9), 339-342. [PMID: 2549018]
9. Leong, G.B.; Silva, J.A. Neuroleptic-induced akathisia and violence: a review. J. Forensic Sci., 2003, 48(1), 187-189. [http://dx.doi. org/10.1520/JFS2002173][PMID: 12570226]
10. Bratti, I.M.; Kane, J.M.; Marder, S.R. Chronic restlessness with antipsychotics. Am. J. Psychiatry, 2007, 164(11), 1648-1654. [http://dx.doi.org/10.1176/appi.ajp.2007.07071150] [PMID: 17974927]
11. Bhidayasiri, R.; Boonyawairoj, S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad. Med. J., 2011, 87(1024), 132-141. [http://dx.doi.org/10.1136/pgmj.2010.103234] [PMID: 21131613]
12. Lee, M.J.; Lin, P.Y.; Chang, Y.Y.; Chong, M.Y.; Lee, Y. Antipsychotics-induced tardive syndrome: a retrospective epidemiological study. Clin. Neuropharmacol., 2014, 37(4), 111-115. [http://dx.doi.org/10.1097/WNF.0000000000000040] [PMID: 24992086]
13. Munetz, M.R.; Cornes, C.L. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr. Psychiatry, 1982, 23(4), 345-352. [http://dx.doi.org/10.1016/0010-440X(82)90084-0] [PMID: 6126315]
14. Lang, A.E. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov. Disord., 1994, 9(2), 188-192. [http://dx.doi.org/10.1002/mds.870090211][PMID: 8196681]
15. Stubbs, J.H.; Halstead, S.M. Pseudoakathisia: a review and two case reports. Compr. Psychiatry, 2000, 41(1), 70-72. [http://dx.doi. org/10.1016/S0010-440X(00)90134-2][PMID: 10646622]
16. Halstead, S.M.; Barnes, T.R.; Speller, J.C. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br. J. Psychiatry, 1994, 164(2), 177-183. [http://dx.doi.org/10.1192/bjp.164.2.177][PMID: 7909711]
17. Janno, S.; Holi, M.; Tuisku, K.; Wahlbeck, K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am. J. Psychiatry, 2004, 161(1), 160-163. [http://dx.doi.org/10.1176/appi.ajp.161.1.160] [PMID: 14702266]
18. Sahoo, S.; Ameen, S. Acute nocturnal akathisia induced by clozapine. J. Clin. Psychopharmacol., 2007, 27(2), 205. [http://dx.doi.org/10.1097/01.jcp.0000248618.49789.55][PMID: 17414247]
19. Berna, F.; Misdrahi, D.; Boyer, L.; Aouizerate, B.; Brunel, L.; Capdevielle, D.; Chereau, I.; Danion, J.M.; Dorey, J.M.; Dubertret, C.; Dubreucq, J.; Faget, C.; Gabayet, F.; Lancon, C.; Mallet, J.; Rey, R.; Passerieux, C.; Schandrin, A.; Schurhoff, F.; Tronche, A.M.; Urbach, M.; Vidailhet, P.; Llorca, P.M.; Fond, G. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr. Res., 2015, 169(1-3), 255-261. [http://dx.doi.org/10.1016/j.schres.2015.10.040][PMID: 26589388]
20. Saddichha, S.; Kumar, R.; Babu, G.N.; Chandra, P. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. J. Clin. Pharmacol., 2012, 52(9), 1448-1449. [http://dx.doi.org/10.1177/0091270011414573] [PMID: 21903892]
21. Spielmans, G.I.; Berman, M.I.; Linardatos, E.; Rosenlicht, N.Z.; Perry, A.; Tsai, A.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med., 2013, 10(3), e1001403. [http://dx.doi.org/10.1371/journal.pmed.1001403][PMID: 23554581]
22. Oh, G.H.; Yu, J-C.; Choi, K-S.; Joo, E-J.; Jeong, S-H. Simultaneous comparison of efficacy and tolerability of secondgeneration antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. PsychiatryInvestig., 2015, 12(1), 46-54. [http://dx.doi.org/10.4306/pi.2015. 12.1.46][PMID: 25670945]
23. Zhang, J.P.; Gallego, J.A.; Robinson, D.G.; Malhotra, A.K.; Kane, J.M.; Correll, C.U. Efficacy and safety of individual secondgeneration vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol., 2013, 16(6), 1205-1218. [http://dx.doi.org/10.1017/S1461145712001277] [PMID: 23199972]
24. Haddad, P.M.; Das, A.; Keyhani, S.; Chaudhry, I.B. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J. Psychopharmacol. (Oxford), 2012, 26(5)(Suppl.), 15-26. [http://dx.doi.org/10.1177/0269881111424929][PMID: 22057019]
25. Hawthorne, J.M.; Caley, C.F. Extrapyramidal reactions associated with serotonergic antidepressants. Ann. Pharmacother., 2015, 49(10), 1136-1152. [http://dx.doi.org/10.1177/1060028015594812] [PMID: 26185277]
26. Anderson, HD; Pace, WD; Libby, AM; West, DR; Valuck, RJ Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther., 2012, 34(1), 113-23. [http://dx.doi.org/10.1016/j.clinthera.2011.11.024]
27. Madhusoodanan, S.; Alexeenko, L.; Sanders, R.; Brenner, R. Extrapyramidal symptoms associated with antidepressantsa review of the literature and an analysis of spontaneous reports. Ann. Clin. Psychiatry, 2010, 22(3), 148-156. [PMID: 20680187]
28. Dag, E.; Gokce, B.; Buturak, S.V.; Tiryaki, D.; Erdemoglu, A.K. Pregabalin-induced akathisia. Ann. Pharmacother., 2013, 47(4), 592-593. [http://dx.doi.org/10.1345/aph.1R699][PMID: 23535811]
29. Ponde, M.P.; Freire, A.C. Increased anxiety, akathisia, and suicidal thoughts in patients with mood disorder on aripiprazole and lamotrigine. Case Report. Psychiatry, 2015, 2015, 419746. [http://dx.doi.org/10.1155/2015/419746][PMID: 26509095]
30. Riesselman, A.; El-Mallakh, R.S. Akathisia with azithromycin. Ann. Pharmacother., 2015, 49(5), 609. [http://dx.doi.org/10.1177/1060028015570728][PMID: 25870444]
31. Dressler, D. Tardive dystonic syndrome induced by the calciumchannel blocker amlodipine. J. Neural. Transm (Vienna), 2014, 121(4), 367-369. [http://dx.doi.org/10.1007/s00702-013-1108-8] [PMID: 24169926]
32. Asser, A.; Taba, P. Psychostimulants and movement disorders. Front. Neurol., 2015, 6, 75. [http://dx.doi.org/10.3389/fneur.2015. 00075][PMID: 25941511]
33. Mohammad, S.S.; Wallace, G.; Ramanathan, S.; Brilot, F.; Dale, R.C. Antipsychotic-induced akathisia and neuroleptic malignant syndrome in anti-NMDAR encephalitis. Ann. Clin. Psychiatry, 2014, 26(4), 297-298. [PMID: 25166486]
34. Kemp, D.E. Managing the side effects associated with commonly used treatments for bipolar depression. J. Affect. Disord., 2014, 169(Suppl. 1), S34-S44. [http://dx.doi.org/10.1016/S0165-0327 (14)70007-2][PMID: 25533913]
35. Marras, C.; Chaudhuri, K.R. Nonmotor features of Parkinsons disease subtypes. Mov. Disord., 2016, 31(8), 1095-1102. [http://dx.doi.org/10.1002/mds.26510][PMID: 26861861]
36. Nordstrom, P.; Michaelsson, K.; Gustafson, Y.; Nordstrom, A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann. Neurol., 2014, 75(3), 374-381. [http://dx.doi. org/10.1002/ana.24101][PMID: 24812697]
37. Shuen, J.A.; Chen, M.; Gloss, B.; Calakos, N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J. Neurosci., 2008, 28(11), 2681-2685. [http://dx.doi.org/10.1523/JNEUROSCI.5492-07.2008] [PMID: 18337395]
38. Bateup, H.S.; Santini, E.; Shen, W.; Birnbaum, S.; Valjent, E.; Surmeier, D.J.; Fisone, G.; Nestler, E.J.; Greengard, P. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc. Natl. Acad. Sci. USA, 2010, 107(33), 14845-14850. [http://dx.doi.org/10.1073/pnas.1009874107][PMID: 20682746]
39. Shukla, R.; Watakabe, A.; Yamamori, T. mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain. Front. Neural Circuits, 2014, 8, 52. [http://dx.doi.org/10.3389/fncir.2014.00052][PMID: 24904298]
40. Di Matteo, V.; Cacchio, M.; Di Giulio, C.; Esposito, E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol. Biochem. Behav., 2002, 71(4), 727-734. [http://dx.doi.org/10.1016/S0091-3057(01)00705-5] [PMID: 11888564]
41. Adler, L.A.; Angrist, B.; Reiter, S.; Rotrosen, J. Neurolepticinduced akathisia: a review. Psychopharmacology (Berl.), 1989, 97(1), 1-11. [PubMed: 2565586]. [http://dx.doi.org/10.1007/BF00443404] [PMID: 2565586]
42. Poyurovsky, M.; Weizman, A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br. J. Psychiatry, 2001, 179, 4-8. [http://dx.doi.org/10.1192/bjp.179.1.4][PMID: 11435260]
43. Loonen, A.J.; Stahl, S.M. The mechanism of drug-induced akathisia. CNS Spectr., 2011, 16(1), 7-10.[http://dx.doi.org/10.1017/S1092852912000107]
44. Kim, J.H.; Son, Y.D.; Kim, H.K.; Lee, S.Y.; Cho, S.E.; Kim, Y.B.; Cho, Z.H. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. J. Clin. Psychopharmacol., 2011, 31(4), 507-511. [http://dx.doi.org/10.1097/JCP.0b013e318222353a] [PMID: 21694619]
45. Goncalves, J.; Baptista, S.; Silva, A.P. Psychostimulants and brain dysfunction: a review of the relevant neurotoxic effects. Neuropharmacology, 2014, 87, 135-49. [http://dx.doi.org/10.1016/j.neuropharm.2014.01.006]
46. Aberg, K.; Adkins, D.E.; Bukszar, J.; Webb, B.T.; Caroff, S.N.; Miller, D.D.; Sebat, J.; Stroup, S.; Fanous, A.H.; Vladimirov, V.I.; McClay, J.L.; Lieberman, J.A.; Sullivan, P.F.; van den Oord, E.J. Genomewide association study of movement-related adverse antipsychotic effects. Biol. Psychiatry, 2010, 67(3), 279-282. [http://dx.doi.org/10.1016/j.biopsych.2009.08.036] [PMID: 19875103]
47. Crowley, J.J.; Kim, Y.; Szatkiewicz, J.P.; Pratt, A.L.; Quackenbush, C.R.; Adkins, D.E.; van den Oord, E.; Bogue, M.A.; Yang, H.; Wang, W.; Threadgill, D.W.; de Villena, F.P.; McLeod, H.L.; Sullivan, P.F. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm. Genome, 2012, 23(5-6), 322-335. [http://dx.doi.org/10.1007/s00335-011-9385-8] [PMID: 22207321]
48. Bakker, P.R.; Bakker, E.; Amin, N.; van Duijn, C.M.; van Os, J.; van Harten, P.N. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One, 2012, 7(5), e36561. [http://dx.doi.org/10.1371/journal.pone.0036561] [PMID: 22615781]
49. Broadhurst, P.L. Determinants of emotionality in the rat. I. Situational factors. Br. J. Psychol., 1957, 48(1), 1-12. [http://dx.doi. org/10.1111/j.2044-8295.1957.tb00594.x][PMID: 13413179]
50. Le Moal, M.; Cardo, B.; Stinus, L. Influence of ventral mesencephalic lesions on various spontaneous and conditional behaviours in the rat. Physiol. Behav., 1969, 4, 567-574. [http://dx.doi.org/10.1016/0031-9384(69)90156-5]
51. Teicher, M.H.; Klein, D.A.; Andersen, S.L.; Wallace, P. Development of an animal model of fluoxetine akathisia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1995, 19(8), 1305-1319. [http://dx.doi.org/10.1016/0278-5846(95)00268-5] [PMID: 8868211]
52. Casey, D.E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol. Bull., 1991, 27(1), 47-50. [PMID: 1677773]
53. Lublin, H.; Gerlach, J.; Morkeberg, F. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology (Berl.), 1994, 114(3), 495-504. [http://dx.doi.org/10.1007/BF02249341][PMID: 7855208]
54. Bruhwyler, J.; Chleide, E.; Houbeau, G.; Waegeneer, N.; Mercier, M. Differentiation of haloperidol and clozapine using a complex operant schedule in the dog. Pharmacol. Biochem. Behav., 1993, 44(1), 181-189. [http://dx.doi.org/10.1016/0091-3057(93)90297-7] [PMID: 8430121]
55. Sachdev, P.S.; Brune, M. Animal models of acute drug-induced akathisia-a review. Neurosci. Biobehav. Rev., 2000, 24(3), 269-277. [http://dx.doi.org/10.1016/S0149-7634(99)00069-X] [PMID: 10781691]
56. LeMoal, M.; Stinus, L.; Galey, D. Radiofrequency lesion of the ventral mesencephalic tegmentum: neurological and behavioral considerations. Exp. Neurol., 1976, 50(3), 521-535. [http://dx.doi.org/10.1016/0014-4886(76)90024-8][PMID: 943305]
57. Barnes, T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry, 1989, 154, 672-676. [http://dx.doi.org/10.1192/bjp.154. 5.672][PMID: 2574607]
58. Janno, S.; Holi, M.M.; Tuisku, K.; Wahlbeck, K. Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia. Eur. Neuropsychopharmacol., 2005, 15(1), 39-41. [http://dx.doi. org/10.1016/j.euroneuro.2004.05.003][PMID: 15572272]
59. Hirschfeld, R.M.; Keck, P.E., Jr; Kramer, M.; Karcher, K.; Canuso, C.; Eerdekens, M.; Grossman, F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry, 2004, 161(6), 1057-1065. [http://dx.doi.org/10.1176/appi.ajp.161.6.1057] [PMID: 15169694]
60. Forcen, F.E. Akathisia: Is restlessness a primary condition or an adverse drug effect? Curr. Psychiatr., 2015, 14(1), 14-18.
61. Kane, J.M.; Barnes, T.R.; Correll, C.U.; Sachs, G.; Buckley, P.; Eudicone, J.; McQuade, R.; Tran, Q.V.; Pikalov, A., III; Assuncao-Talbott, S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short-and long-term aripiprazole trials. J. Psychopharmacol. (Oxford), 2010, 24(7), 1019-1029. [http://dx.doi.org/10.1177/0269881109348157][PMID: 20008446]
62. Hirose, S. The causes of underdiagnosing akathisia. Schizophr. Bull., 2003, 29(3), 547-558. [http://dx.doi.org/10.1093/oxfordjournals. schbul.a007027][PMID: 14609248]
63. Lohr, J.B.; Eidt, C.A.; Abdulrazzaq, A.A.; Soliman, M.A. The clinical challenges of akathisia. CNS Spectr., 2015, 20(Suppl. 1), 1-14. [http://dx.doi.org/10.1017/S1092852915000838] [PMID: 26683525]
64. Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223. [http://dx.doi.org/10.1056/NEJMoa051688][PMID: 16172203]
65. Kasper, S.; Winkler, D. Addressing the limitations of the CATIE study. World J. Biol. Psychiatry, 2006, 7(2), 126-127. [http://dx.doi.org/10.1080/15622970600685424][PMID: 16684687]
66. Stip, E.; Anselmo, K. Effectiveness of antipsychotics: is the CATIE trial a tsunami? Can. Fam. Phys., 2007, 53(1), 97-98. [PMID: 17872617]
67. Poyurovsky, M. Acute antipsychotic-induced akathisia revisited. Br. J. Psychiatry, 2010, 196(2), 89-91. [http://dx.doi.org/10.1192/bjp.bp.109.070540][PMID: 20118449]
68. Poyurovsky, M.; Pashinian, A.; Weizman, R.; Fuchs, C.; Weizman, A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo-and propranolol-controlled trial. Biol. Psychiatry, 2006, 59(11), 1071-1077. [http://dx.doi.org/10.1016/j.biopsych.2005.12. 007][PMID: 16497273]
69. Kane, J.M.; Fleischhacker, W.W.; Hansen, L.; Perlis, R.; Pikalov, A., III; Assuncao-Talbott, S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry, 2009, 70(5), 627-643. [http://dx.doi.org/10.4088/JCP.08r04210][PMID: 19389331]
70. Stryjer, R.; Strous, R.D.; Bar, F.; Poyurovsky, M.; Weizman, A.; Kotler, M. Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone. Clin. Neuropharmacol., 2003, 26(3), 137-141. [http://dx.doi.org/10.1097/00002826-200305000-00006] [PMID: 12782915]
71. Lima, A.R.; Weiser, K.V.; Bacaltchuk, J.; Barnes, T.R. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst. Rev., 2004, (1), CD003727. [PMID: 14974032]
72. Iqbal, N.; Lambert, T.; Masand, P. Akathisia: problem of history or concern of today. CNS Spectr., 2007, 12(9)(Suppl. 14), 1-13. [http://dx.doi.org/10.1017/S1092852900026201][PMID: 17805218]
73. Lima, A.R.; Bacalcthuk, J.; Barnes, T.R.; Soares-Weiser, K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst. Rev., 2004, (4), CD001946. [PMID: 15495022]
74. Rathbone, J.; Soares-Weiser, K. Anticholinergics for neurolepticinduced acute akathisia. Cochrane Database Syst. Rev., 2006, (4), CD003727. [PMID: 17054182]
75. Baskak, B.; Atbasoglu, E.C.; Ozguven, H.D.; Saka, M.C.; Gogus, A.K. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol., 2007, 27(3), 289-294. [http://dx.doi.org/10.1097/jcp.0b013e3180582439] [PMID: 17502777]
76. Barnes, T.R.; McPhillips, M.A. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br. J. Psychiatry Suppl., 1999, 174(38), 34-43. [PMID: 10884898]
77. Lima, A.R.; Soares-Weiser, K.; Bacaltchuk, J.; Barnes, T.R. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst. Rev., 2002, CD001950(1), CD001950. [http://dx.doi.org/10.1002/14651858.CD001950][PMID: 11869614]
78. Lapa, G.B.; Mathews, T.A.; Harp, J.; Budygin, E.A.; Jones, S.R. Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur. J. Pharmacol., 2005, 506(3), 237-240. [http://dx.doi.org/10.1016/j.ejphar.2004.11.017] [PMID: 15627433]
79. Tanda, G.; Kopajtic, T.A.; Katz, J.L. Cocaine-like neurochemical effects of antihistaminic medications. J. Neurochem., 2008, 106(1), 147-157. [http://dx.doi.org/10.1111/j.1471-4159.2008.05361.x] [PMID: 18363822]
80. Oleson, E.B.; Ferris, M.J.; Espana, R.A.; Harp, J.; Jones, S.R. Effects of the histamine H_ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward. Eur. J. Pharmacol., 2012, 683(1-3), 161-5. [http://dx.doi. org/10.1016/j.ejphar.2012.03.003]
81. Vinson, D.R.; Drotts, D.L. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann. Emerg. Med., 2001, 37(2), 125-131. [http://dx.doi.org/10.1067/mem.2001.113032][PMID: 11174228]
82. Simons, F.E. Advances in H1-antihistamines. N. Engl. J. Med., 2004, 351(21), 2203-2217. [http://dx.doi.org/10.1056/NEJMra033121][PMID: 15548781]
83. Simons, F.E.; Akdis, C.A. Histamine and antihistamines. Middleton's allergy principles and practice. Mosby, Inc, [an affiliate of Elsevier Science]: St Louis, MO, 2008; pp. 1517-1547.
84. Stryjer, R; Rosenzcwaig, S; Bar, F; Ulman, AM; Weizman, A; Spivak, B Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin. Neuropharmacol., 2010, 33(5), 219-222. [http://dx.doi.org/10.1097/WNF.0b013e3181ee7f63]
85. Poyurovsky, M.; Fuchs, C.; Weizman, A. Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. J. Clin. Psychopharmacol., 1998, 18(3), 253-254. [http://dx.doi.org/10.1097/00004714-199806000-00013] [PMID: 9617987]
86. Kumar, R.; Sachdev, P.S. Akathisia and second-generation antipsychotic drugs. Curr. Opin. Psychiatry, 2009, 22(3), 293-299. [http://dx.doi.org/10.1097/YCO.0b013e32832a16da] [PMID: 19378382]
87. Avital, A.; Gross-Isseroff, R.; Stryjer, R.; Hermesh, H.; Weizman, A.; Shiloh, R. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. Eur. Neuropsychopharmacol., 2009, 19(7), 476-482. [http://dx.doi.org/10.1016/j.euroneuro.2009.02.006] [PMID: 19342206]
88. Blaisdell, G.D. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry, 1994, 27(4), 139-146. [http://dx.doi.org/10.1055/s-2007-1014294][PMID: 7972345]
89. Hettema, J.M.; Ross, D.E. A case of aripiprazole-related tardive akathisia and its treatment with ropinirole. J. Clin. Psychiatry, 2007, 68(11), 1814-1815. [http://dx.doi.org/10.4088/JCP.v68n1124e] [PMID: 18052582]
90. Garcia-Borreguero, D.; Larrosa, O.; Williams, A.M.; Albares, J.; Pascual, M.; Palacios, J.C.; Fernandez, C. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology, 2010, 74(23), 1897-1904. [http://dx.doi.org/10.1212/WNL.0b013e3181e1ce73][PMID: 20427750]
91. Pfeffer, G.; Chouinard, G.; Margolese, H.C. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int. Clin. Psychopharmacol., 2005, 20(3), 179-181. [http://dx.doi.org/10.1097/00004850-200505000-00011] [PMID: 15812271]
92. De Berardis, D.; Serroni, N.; Moschetta, F.S.; Martinotti, G.; Di Giannantonio, M. Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin. J. Neuropsychiatry Clin. Neurosci., 2013, 25(2), E9-E10.[http://dx.doi.org/10.1176/appi.neuropsych.12030069][PMID: 23686043]
93. Dolphin, A.C. Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond. Nat. Rev. Neurosci., 2012, 13(8), 542-55. [http://dx.doi.org/10.1038/nrn3311.PMID 22805911]
94. Kukkar, A.; Bali, A.; Singh, N.; Jaggi, A.S. Implications and mechanism of action of gabapentin in neuropathic pain. Arch. Pharm. Res., 2013, 36(3), 237-251. [http://dx.doi.org/10.1007/s12272-013-0057-y] [PMID: 23435945]
95. Hendrich, J.; Van Minh, A.T.; Heblich, F.; Nieto-Rostro, M.; Watschinger, K.; Striessnig, J.; Wratten, J.; Davies, A.; Dolphin, A.C. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad Sci. USA, 2008, 105(9), 3628-33. [http://dx.doi.org/10.1073/pnas.0708930105]
96. Eroglu, C.; Allen, N.J.; Susman, M.W.; O'Rourke, N.A.; Park, C.Y.; Ozkan, E.; Chakraborty, C.; Mulinyawe, S.B.; Annis, D.S.; Huberman, A.D.; Green, E.M.; Lawler, J.; Dolmetsch, R.; Garcia, K.C.; Smith, S.J.; Luo, Z.D.; Rosenthal, A.; Mosher, D.F.; Barres, B.A. Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report. Ther. Adv. Psychopharmacol., 2014, 4(2), 100-2. [http://dx.doi.org/10.1177/2045125314525433]
97. Sullivan, M.A.; Wilbur, R. Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report. Ther. Adv. Psychopharmacol., 2014, 4(2), 100-102. [http://dx.doi.org/10.1177/2045125314525433][PMID: 24688760]
98. Lerner, V.; Bergman, J.; Statsenko, N.; Miodownik, C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2004, 65(11), 1550-1554. [http://dx.doi.org/10.4088/JCP.v65n1118] [PMID: 15554771]
99. Miodownik, C.; Lerner, V.; Statsenko, N.; Dwolatzky, T.; Nemets, B.; Berzak, E.; Bergman, J. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin. Neuropharmacol., 2006, 29 (2), 68-72. [http://dx.doi.org/10.1097/00002826-200603000-00002] [PMID: 16614537]
100. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K.Q.; Bush, A.I. N-acetyl cysteine as a glutathione precursor for schizophreniaa double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64(5), 361-368. [http://dx.doi.org/10.1016/j. biopsych.2008.03.004][PMID: 18436195];